Sep 29, 2020
Enesi Pharma's ImplaVax®-Enabled, Solid-Dose Modified Live Virus Vaccine Produces Neutralising Antibody and T-Cell Responses Equivalent to Liquid Vaccine Delivered via Needle and Syringe
Sep 28, 2020
Enesi Pharma Appoints Vaccine Development Expert Dr Keith Howard as Chief Scientific Officer to Lead Research & Development of Novel ImplaVax® Solid-dose, Needle-free Vaccination Products
Sep 03, 2020
Enesi Pharma to Develop Thermostable Solid Dose DNA Vaccine Targeting Zika Virus under New Partnership with The University of Adelaide
Oct 29, 2019
Enesi Pharma Awarded Grant Funding to Develop and Evaluate ImplaVax®-enabled Solid Dose Vaccines Targeting Measles and Rubella
Oct 22, 2019
Enesi Pharma to Participate at the World Vaccine Congress Europe from 29th-31st October 2019
Sep 24, 2019
Enesi Pharma Secures Innovate UK Funding to Enable Scalable Aseptic Manufacturing of ImplaVax®-enabled Solid Dose Viral Vector Vaccines
Jul 01, 2019
Enesi Pharma Adds Global Vaccine and Infectious Disease Expert Steven Chatfield to Its Scientific Advisory Board
Apr 15, 2019
Enesi Pharma and BARDA Drive Enter Public-Private Partnership to Develop ImplaVax® Solid Dose Vaccine Delivery Technology Against Influenza
Apr 09, 2019
Enesi Pharma and University of Oxford Collaborate to Target Plague With a Novel ImplaVax®-enabled Adenovirus-based Solid Dose Vaccine
Nov 05, 2018
Enesi Pharma and Sementis Sign R&D Collaboration Focused on Needle-free Solid Dose Vaccines for Peanut Allergy and Chikungunya/Zika Infection
Oct 01, 2018
Enesi Pharma and Public Health England Enter R&D Collaboration for Novel Needle-Free Solid-Dose Vaccine for Emergent Threat Pathogens
Sep 24, 2018
Enesi Pharma and Walter Reed Army Institute of Research (WRAIR) Sign Cooperative R&D Agreement (CRADA) for Needle-Free Solid-Dose Vaccine for Shigella Infection
Nov 06, 2017
Enesi Pharma Appoints New International Scientific Advisory Board
Oct 10, 2017
Enesi Pharma Debuts at World Vaccine Congress